Behavior of uptake of moisture by drugs and excipients under accelerated conditions of temperature and humidity in the absence and the presence of light. 1. Pure anti-tuberculosis drugs and their combinations

International Journal of Pharmaceutics

Volumn 245, Issue 1-2, 2002, Pages 37-44

  Singh, Saranjit ^a   Bhutani, H ^a   Mariappan, T T ^a   Kaur, Harpinder ^a   Bajaj, M ^a   Pakhale, S P ^a  

^a Department of Pharmaceutics   (India)

Author keywords

Accelerated conditions; Combinations; Dark; Ethambutol; Isoniazid; Light; Moisture gain; Pure drugs; Pyrazinamide; Rifampicin; Storage

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ARTICLE; DARKNESS; DRUG PURITY; DRUG UPTAKE; HUMIDITY; LIGHT; MOISTURE; PRIORITY JOURNAL; TEMPERATURE; WEIGHT GAIN;

ADSORPTION; ANTITUBERCULAR AGENTS; DARKNESS; DRUG COMBINATIONS; DRUG STABILITY; ETHAMBUTOL; EXCIPIENTS; ISONIAZID; LIGHT; PYRAZINAMIDE; RIFAMPIN; TEMPERATURE; WATER;

EID: 0036806555     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(02)00340-X     Document Type: Article

References (8)

1. Acocella G. Human bioavailability studies. Bull. Int. Union Tuberc. Lung Dis. 64:1989;38-40.
2. ICH, 1996. Photostability testing of new drug substances and products. International Conference on Harmonization, Geneva.
3. Long M.W., Snider D.R., Farer L.S. US Public Health service cooperative trial of three RIF-INH regimens in the treatment of pulmonary tuberculosis. Am. Rev. Respir. Dis. 119:1979;879-894.
4. Mohan, B., 2001. Development of a Stability Indicating Assay Method for Rifampicin, Isoniazid, and Pyrazinamide in Combination, M.Pharm. thesis, NIPER. S.A.S. Nagar, India.
5. Pillai G., Fourie P.B., Padayatchi N., Onyebujoh P.C., McIlleron H., Smith P.J., Gabriels G. Recent bioequivalence studies on fixed dose combination antituberculosis drug formulations available on the global market. Int. J. Tuberc. Lung Dis. 3:1999;S317-S321.
6. Singh S., Mariappan T.T., Sharda N., Singh B. Degradation of rifampicin, isoniazid and pyrazinamide from prepared mixtures and marketed single and combination products under acid conditions. Pharm. Pharmacol. Commun. 6:2000a;491-494.
7. Singh S., Mariappan T.T., Sharda N., Kumar S., Chakraborti A.K. The reason for an increase in decomposition of rifampicin in the presence of isoniazid under acid conditions. Pharm. Pharmacol. Commun. 6:2000b;405-410.
8. Singh S., Mariappan T.T., Sankar R., Sharda N., Singh B. A critical review of the probable reasons for the variable bioavailability of rifampicin from anti-tubercular fixed-dose combination (FDC) products, and the likely solutions to the problem. Int. J. Pharm. 228:2001;5-17.